Reversal of Dabigatran with Haemodialysis in a Patient Requiring Decompression for Cord Compression from an Epidural Abscess

Nephrology

Volumn 18, Issue 8, 2013, Pages 580-582

  Lowe, Malcolm P ^a   Collins, John ^a   Yehia, Maha ^a   Eaddy, Nicola ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DABIGATRAN; FLUCLOXACILLIN; FUROSEMIDE;

AGED; ANTIBIOTIC THERAPY; CASE REPORT; CREATININE BLOOD LEVEL; EPIDURAL ABSCESS; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; LETTER; LUNG EDEMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; SPINAL CORD COMPRESSION; SPINAL CORD DECOMPRESSION; THROMBIN TIME;

EID: 84881387930     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12100     Document Type: Letter

References (5)

1. Stangier J, Rathgen K, Stähle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. Clin. Pharmacokinet. 2010; 49: 259-268.
2. Wienen W, Stassen JM, Priepke H, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb. Haemost. 2007; 98: 155-162. (Pubitemid 47078782)
3. Chang DN, Dager WE, Chin AI,. Removal of dabigatran by hemodialysis. Am. J. Kidney Dis. 2013; 61: 487-489.
4. van Ryn J, Hauel N, Waldmann L, et al. Dabigatran inhibits both clot-bound and fluid phase thrombin in vitro: Effects compared to heparin and hirudin (abstract). Blood 2007; 110: 3998.
5. Strangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J. Clin. Pharmacol. 2005; 45: 555-563. (Pubitemid 40562946)